Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Purdue partners with Eli Lilly and Merck to launch the Young Institute Pharmaceutical Manufacturing Consortium, focusing on sterile injectables.

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Eli Lilly, Novo Nordisk, CVS Health, CVS Pharmacy, Caremark Health, United Health Group, Express Scripts Pharmacy and more are named in the lawsuit, accused of managing a pricing and kickback ...

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity ... health-care products purveyor Haleon. The largest pharmacy-benefit managers hiked the prices of certain ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

"2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 with strong financial and operational performance," continued Ricks. "Sales of Mounjaro and ...

Eli Lilly is leading a push with other pharmaceutical companies to request a pause in the Biden administration's drug pricing negotiations, even as officials prepare to release a new list of ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in ...